Kids who have irritable bowel syndrome with constipation (IBS-C) now have a new treatment option as the Food and Drug Administration (FDA) this month approved linaclotide for pediatric patients 7 years and older. There is no known underlying cause for IBS-C in children, and symptoms include chronic constipation and abdominal pain. Linaclotide is the first treatment approved for IBS-C in pediatric patients with a recommended dose of 145 mcg orally once daily. A 12-week, double-blind, …
Read More







